I apologize: I missed that it was directed to me.
For the Canadian pull incentive, you're probably talking about two or three drugs at a time, given that it's likely to not be needed after five years. That's a guarantee of $13 million U.S. Really, on average, only about half of that would be spent per year.
CARB-X has asked Canada for something in the range of $6 million Canadian per year. That would cover our pull incentive as we provide charitable, non-dilutive help to companies worldwide, taking them from the hit-to-lead stage to the end of the first-in-human stage.
On the proposal from Dr. Wright, there are two of them that I can think of.
One is to create a specific committee within CIHR, which funds AMR, and increasing that. The second was his request for something like an SBIR. Really, that's less than $1 million or $2 million per year, because these awards are typically $200,000 to $300,000 U.S. There aren't that many companies that actually would use them.
Together, that's a pretty comprehensive program. It would guarantee Canadian research continuing, going forward, and make sure that these new drugs are actually and practically available in Canada without financial barriers to patients.